About Us


Revive Therapeutics Ltd. is a publicly-traded company listed on the OTCQB: RVVTF in the U.S. and the TSX Venture: RVV in Canada.

 

Revive's lead product is in the treatment for acute gout flares, which completed a Phase 2a study in the U.S.

 

Also, Revive is advancing developments in rare diseases such as, Cystinuria, which was granted FDA Orphan Drug Status, Wilson's disease and Rett syndrome (partnered with Rettsyndrome.org).

Read more

news

News

January 20, 2016

Revive Therapeutics Announces Issuance of U.S. Patent Related to Bucillamine in the Treatment of Gout

Read more
January 19, 2016

Revive Therapeutics to Present at Noble Capital Markets' Investor Conference

Read more
December 08, 2015

Revive Therapeutics Announces DTC Eligibility of Its Common Shares

Read more
December 07, 2015

Revive Therapeutics Retains the Ruth Group to Build U.S. Investment Community Awareness

Read more
December 01, 2015

Revive Therapeutics Announces Positive Final Results from Its Phase 2a Study for the Treatment of Acute Gout Flares

Read more
Newsletter
Corporate presentation

 

Presentation

January 2016